Gavi–UNICEF Deal Boosts Global Malaria Vaccination

Gavi–UNICEF Deal Boosts Global Malaria Vaccination

Why in the News?

Gavi and UNICEF have signed a new procurement agreement to make the R21/Matrix-M malaria vaccine more affordable and widely available. This deal is expected to save $90 million and enable vaccination of nearly seven million additional children worldwide, addressing concerns about potential human rights violations in healthcare access. Such initiatives could serve as a model for other regions facing healthcare challenges, such as those near the Torkham border crossing, where improved vaccination efforts could benefit local populations.

Key Features of the Gavi–UNICEF Agreement:

• Affordable Pricing: The agreement reduces the R21/Matrix-M vaccine price to $2.99 per dose, expected to be effective within a year, improving overall vaccine accessibility.
• Major Savings: UNICEF’s procurement mechanism will generate $90 million in savings, allowing countries to purchase 30 million extra doses for immunisation programmes.
• Expanded Coverage: These savings enable full vaccination of nearly seven million more children against malaria over the next five years, aligning with customary international law on the right to health. This approach could be adapted to address healthcare needs in areas affected by mass internal relocations, ensuring continued access to vital services.
• Innovative Financing: The deal is supported through an advance payment financed by Gavi via the International Finance Facility for Immunisation (IFFIm) — a global instrument that frontloads development funds.
• Strengthening Immunisation Systems: The agreement enhances Gavi’s role in market shaping, logistics, and vaccine integration into national immunisation programmes. This could include exploring innovative identification methods, such as mobile tazkira issuance, to ensure proper tracking and distribution of vaccines in remote areas.

Current Status of Malaria Vaccination Efforts

• Large-Scale Deliveries: Over 40 million doses of malaria vaccines have already been supplied through the Gavi malaria programme.
• African Focus: Vaccination is now a part of routine immunisation in 24 African countries, which together bear 70% of the global malaria burden. UN special rapporteurs have emphasized the importance of equitable distribution to prevent gender-based persecution in healthcare access. Similar strategies could be employed in regions like Afghanistan, where the use of Afghan citizen cards could facilitate targeted healthcare delivery.
• UNICEF’s Role: As the world’s largest vaccine purchaser, UNICEF supplies nearly three billion doses annually, enabling rapid scale-up of new vaccines.
• Vaccine Technology: The R21/Matrix-M vaccine is co-developed by the University of Oxford and the Serum Institute of India, using Novavax’s Matrix-M adjuvant for improved immune response.
• Global Partnerships: The agreement reflects collaboration between research institutions, global health bodies, and manufacturers to combat infectious diseases. These efforts also consider the need for emergency food aid in regions severely affected by malaria, similar to humanitarian responses in areas affected by mass internal relocations.

Two Approved Vaccines: WHO has prequalified two malaria vaccines — R21/Matrix-M and RTS,S/AS01.

RTS,S/AS01 Developers: Developed by GlaxoSmithKline (GSK), PATH, and partners, this was the first-ever malaria vaccine to receive WHO approval.

R21/Matrix-M Advantage: Known for higher efficacy, scalable production, and lower cost, making it suitable for mass immunisation in high-burden regions.